top of page

Ask the Expert

Public·3 members

t2diabetesnetwork
t2diabetesnetwork

What’s the difference between GLP-1 and SGLT2 medications?

Great question! Both GLP-1 and SGLT2 medications are used to treat type 2 diabetes, but they work in different ways.


GLP-1 medications (like Ozempic or Trulicity) are usually given as weekly injections. They help your body release more insulin when you eat, slow down how quickly food leaves your stomach, and can help you feel full longer—which often leads to some weight loss. Many people find these medications helpful for both blood sugar control and weight management, but they can sometimes cause nausea or stomach upset.


SGLT2 medications (like Jardiance or Farxiga) are taken as daily pills. They work by helping your kidneys get rid of extra sugar through your urine. This not only lowers blood sugar, but can also help protect your heart and kidneys. The main side effects are needing to pee more often and, in some cases, a higher risk of urinary tract infections.


diabetes drugs

GLP-1s are mostly injections, help with blood sugar and weight, but can cause some stomach issues. SGLT2s are pills, help your body flush out sugar, and are good for heart and kidney health, but can cause more frequent urination.


Your doctor will help you choose the best option for your needs. If you want to learn more, check out this research:



GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off - Cardiovascular Diabetology
cardiab.biomedcentral.com
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off - Cardiovascular Diabetology
Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications can identify a subgroup of patients with T2D at high risk of mortality who are likely to achieve the greatest benefit from newer glucose-lowering agents. Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE). The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke. The most striking difference between the two classes of drugs relates to the amelioration on hospitalization for HF, as the benefit of SGLT-2 inhibitors surpass by threefold that obtained with GLP-1RA. Despite this, GLP-1RA also exert a significant benefit on HF which suggest their use when SGLT-2 inhibitors are contraindicated or not tolerated. The difference between the two classes is less impressive for the kidney outcome. Overall, the results of CVOTs published so far seems to suggest that the gap between the cardiorenal benefits of SGLT-2 and GLP-1RA is narrowing.


18 Views

Members

  • geminiwin87geminiwin87
    geminiwin87
  • t2diabetesnetwork
    t2diabetesnetwork
  • Florencio Lee
    Florencio Lee
bottom of page